1314734-59-2

Usage

Uses

Used in Medicinal Chemistry:
5-bromo-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[3,4-b]pyridine-3-carbaldehyde is used as a building block or intermediate in the synthesis of pharmaceutical compounds due to its unique structure and potential biological activity. It can be incorporated into the design and development of new drugs with specific therapeutic properties.
Used in Drug Discovery:
In the field of drug discovery, 5-bromo-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[3,4-b]pyridine-3-carbaldehyde serves as a valuable research tool for studying biological pathways and drug targets. Its unique structure allows researchers to explore its interactions with various biological systems, potentially leading to the identification of new drug candidates for various therapeutic indications.
Used in Pharmaceutical Compounds Synthesis:
5-bromo-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[3,4-b]pyridine-3-carbaldehyde is used as a key component in the synthesis of pharmaceutical compounds, contributing to the development of novel therapeutic agents with improved efficacy and selectivity.
Used in Research and Development:
In the research and development of new drugs, 5-bromo-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[3,4-b]pyridine-3-carbaldehyde plays a crucial role as a starting material or intermediate in the synthesis of potential drug candidates. Further investigation of its properties and applications may lead to the discovery of innovative therapeutic agents for a wide range of medical conditions.

Upstream product

• 110-87-2 3,4-dihydro-2H-pyran 
• 885223-65-4 5-bromo-3-methyl-1H-pyrazolo[3,4-b]pyridine 
• 1314734-58-1 5-bromo-N-methoxy-N-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[3,4-b]pyridine-3-carboxamide 
• 1314734-57-0 5-bromo-N-methoxy-N-methyl-1H-pyrazolo[3,4-b]pyridine-3-carboxamide 
• 916325-85-4 5-bromo-1H-pyrazolo[3,4-b]pyridine-3-carboxylic acid 
• 916325-84-3 methyl 5-bromo-1H-pyrazolo[3,4-b]pyridine-3-carboxylate 
• 916325-83-2 pyrazolo[3,4-b]pyridine-3-carboxylic acid methyl ester 
• 116855-08-4 1H-pyrazolo[3,4-b]pyridine-3-carboxylic acid 
• 131674-39-0 2-chloro-3-(1-hydroxyethyl)pyridine 
• 116834-96-9 3-methyl-1H-pyrazolo[3,4b]pyridine 
• 109-09-1 2-chloropyridine 
• 55676-21-6 3-acetyl-2-chloropyridine 
• 916326-37-9 5-bromo-1H-pyrazolo[3,4-b]pyridine-3-carbaldehyde 
• 766-11-0 5-bromo-2-fluoropyridine 

Downstream Products

• 1314734-68-3 1-(tetrahydro-2H-pyran-2-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazolo[3,4-b]pyridine-3-carbaldehyde 

Relevant academic research and scientific papers

Synthetic method of 3-formyl-1H-pyrazolo [3, 4-b] pyridine-5-carboxylic acid methyl ester

The invention discloses a synthetic method of 3-formyl-1H-pyrazolo [3, 4-b] pyridine-5-carboxylic acid methyl ester. The method comprises the following steps: by taking 5-bromo-1H-pyrazolo [3, 4-b] pyridine-3-carboxylic acid as a raw material, carrying out condensation to obtain weinreb amide 5-bromo-N-methoxy-N-methyl-1H-pyrazolo [3, 4-b] pyridine-3-carboxamide; carrying out DHP protection to obtain 5-bromo-N-methoxy-N-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo [3, 4-b]pyridine-3-formamide; reducing the weinreb amide by using lithium aluminum hydride to obtain 5-bromine-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo [3, 4-b] pyridine-3-formaldehyde; carrying out carbonyl insertion reaction on 5-bromine-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo [3, 4-b] pyridine-3-formaldehyde to obtain 3-formyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo [3, 4-b] pyridine-5-carboxylic acid methyl ester, and finally, carrying out THP removal protection to obtain the product 3-formyl-1H-pyrazolo [3, 4-b] pyridine-5-carboxylic acid methyl ester. The route is mild in reaction condition, simple in subsequent operation and environment-friendly, the product is prepared with high yield and high purity, and the method is suitable for industrial process amplification.

SOLID FORMS OF 1-(5-(3-(7-(3-FLUOROPHENYL)-3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDIN-5-YL)PYRIDIN-3-YL)-N,N-DIMETHYLMETHANAMINE

The present application relates to two crystalline polymorphic forms, crystalline methanol, ethanol and tetrahydrofuran solvates and a crystalline hydrate of the compound l-(5-(3-(7-(3-fluorophenyl)-3H- imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3- yl)-N,N-dimethylmethanamine (Ipivivint), to a pharmaceutical composition comprising them and their medical use for the treatment of disorders characterized by the activation of of the Wnt signaling pathway selected from cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease, osteoarthritis and idiopathic pulmonary fibrosis. Also claimed is a process for the preparation of compounds of Formula (I) by reacting a starting material of Formula (A1) with a compound of Formula (A2).

3-(1H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINE AND THERAPEUTIC USES THEREOF

Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF

Provided herein are compounds according to Formulas (I) or (II) and pharmaceutically acceptable salts thereof, and compositions comprising the same, for use in various methods, including treating cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease, osteoarthritis, idiopathic pulmonary fibrosis and neurological conditions/disorders/diseases.

1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF

Provided herein are compounds according to Formula (I) and pharmaceutically acceptable salts thereof, and compositions comprising the same, for use in various methods, including treating cancers such as colon, ovarian, pancreatic, breast, liver, prostate and hematologic cancers.